Skip to main content
OpenTrials
Completed

NCT Number: NCT04690335

Human Challenge Study to Evaluate the Efficacy of MV-012-968 Vaccine

The purpose of this research study is to evaluate whether the investigational, live attenuated, intranasally delivered vaccine MV-012-968 ('study vaccine') may have prophylactic efficacy against symptomatic RSV infection when administered to adults 18-45 years of age in the Human Viral Challenge model.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

RSV Infection Infections Mononegavirales Infections Paramyxoviridae Infections Pneumovirus Infections RNA Virus Infections Respiratory Syncytial Virus Infections Virus Diseases

Age range

18 year–45 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

hVIVO Services Ltd

London, E1 2AX, United Kingdom

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Key Inclusion Criteria:

  • An informed consent document signed and dated by the participant and the Investigator.
  • Aged between 18 and 45 years old on the day of signing the consent form.
  • In good general health with no history, or current evidence, of clinically significant medical conditions (including respiratory, cardiac and immunodeficiency), and no clinically significant test abnormalities that will interfere with participant safety, as defined by medical history, physical examination (including vital signs), electrocardiogram (ECG), and routine laboratory tests as determined by the Investigator.
  • A documented medical history prior to enrolment.
  • Females of child bearing potential must have a negative pregnancy test prior to enrollment.
  • Females and Males must agree to adhere to the highly effective contraceptive requirements of the study from 2 weeks prior to the first study visit until 90 days after the date of study vaccination.
  • Sero-suitable to the challenge virus, as defined in the study Analytical Plan.

Exclusion criteria

  • History of symptoms or signs suggestive of upper or lower respiratory tract infection within 4 weeks prior to the first study visit
  • Rhinitis which is clinically active
  • History of moderate to severe rhinitis
  • Acute sinusitis during Screening
  • Use of corticosteroid in respiratory tract (e.g. nasal or inhaled steroid) in the 30 days leading up to study vaccination
  • Females who are breastfeeding or have been pregnant within 6 months prior to the study
  • Participants who have smoked ≥ 10 pack years at any time [10 pack years is equivalent to one pack of 20 cigarettes a day for 10 years])
  • Positive human immunodeficiency virus (HIV), active hepatitis A (HAV), B (HBV), or C (HCV) test
  • Those employed or immediate relatives of those employed at hVIVO or the Sponsor
  • Participants may not live or work in direct close contact with, or live with anyone whose work brings them into direct close contact with, children under 2 years of age
  • Any other finding that, in the opinion of the Investigator, deems the participant unsuitable for the study

Treatment and study plan

MV-012-968

Biological

MV-012-968 is a recombinant, live attenuated RSV vaccine.

Placebo

Other

Saline solution

Primary outcomes

  1. Frequency of symptomatic RSV infection, as defined as the occurrence of both:

    Time frame: 10 days (days 2 to 12)

    • At least 1 quantifiable plaque assay sample in nasal wash specimens and
    • Symptoms meeting either: (i) a symptom of any grade from 2 different symptom categories from the participant Symptom Diary Card [SDC] (Upper Respiratory, Lower Respiratory, Systemic) or (ii) at least 1 Grade 2 upper or lower respiratory symptom from the participant SDC

Secondary outcomes

  1. Frequency of symptomatic RSV infection, as defined as occurrence of both:

    Time frame: 10 days (days 2 to 12)

    • Two Quantifiable RT-qPCR samples on 2 consecutive days (i.e. at least 1 on each of 2 consecutive days) in nasal wash specimens and
    • Symptoms meeting either: (i) a symptom of any grade from 2 different symptom categories from the SDC (Upper Respiratory, Lower Respiratory, Systemic) or (ii) at least 1 Grade 2 upper or lower respiratory symptom from the participant SDC

  2. Frequency of RSV infection, as defined as the occurrence of 2 quantifiable RT-qPCR samples on 2 consecutive days (i.e. at least 1 on each of 2 consecutive days) in nasal wash specimens

    Time frame: 10 days (Day 2 to 12)

  3. Frequency of RSV infection, as defined as the occurrence of at least 1 quantifiable plaque assay sample in nasal wash specimens

    Time frame: 10 days (Day 2 to 12)

  4. Mean daily total symptom score using the SDC

    Time frame: 10 days (Day 2 to 12)

  5. Mean daily weight of nasal (mucus) discharge

    Time frame: 10 days (Day 2 to 12)

  6. RSV load Area Under the Curve (AUC), as measured by RT-qPCR analysis of nasal wash specimens

    Time frame: 10 days (Day 2 to 12)

  7. Peak RSV load, as measured by RT-qPCR of nasal wash specimens

    Time frame: 10 days (Day 2 to 12)

  8. Frequency of solicited adverse events (AEs) as reported in the Subject Vaccination Diary Card, categorized by severity. Solicited AEs are predefined AEs that may occur after study vaccine administration.

    Time frame: Time Frame: 7 days (Day -28 to -21)

  9. Frequency of unsolicited AEs after study vaccination, categorized by severity and by study vaccine relatedness.

    Time frame: 28 days (Day -28 to 0)

    Unsolicited AEs are any untoward medical occurrences in a participant administered the study vaccine, regardless of causal relationship to the study vaccine. Unsolicited AEs can include unfavorable and unintended signs (including abnormal laboratory findings), symptoms, or diseases temporally associated with the use of the study vaccine.

  10. Frequency of unsolicited AEs after RSV-A challenge, categorized by severity and by study vaccine relatedness.

    Time frame: 29 days (Day 0 to 28)

  11. Frequency of serious AEs (SAEs) after study vaccination, categorized by study vaccine relatedness.

    Time frame: 180 days (Day -28 to 152)

    SAEs are AEs, whether considered causally related to the study vaccine or not, that threaten life or result in any of the following: death, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions, or congenital anomaly/birth defect.

  12. Frequency of medically attended AEs (MAEs) after study vaccination, categorized by study vaccine relatedness.

    Time frame: 180 days (Day -28 to 152)

    MAEs are AEs, whether considered causally related to the study vaccine or not, with unscheduled medically attended visits, such as urgent care visits, acute primary care visits, emergency department visits, or other previously unplanned visits to a medical provider. Scheduled medical visits such as routine physicals, wellness checks, 'checkups', and vaccinations, are not considered MAEs

Sponsors and collaborators

Lead sponsor

Meissa Vaccines, Inc.

Industry

Collaborators

  • Hvivo

Registry information

Official study title

A Randomised, Phase 2a, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Prophylactic Efficacy of MV-012-968 Against Respiratory Syncytial Virus (RSV) Infection in the Virus Challenge Model.

Important dates

Study start
2020
Primary completion
2021
Study completion
2021
First posted
Dec 30, 2020
Registry last updated
Aug 4, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.